These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21563774)

  • 1. A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease.
    Li H; Wang L; Yan X; Liu Q; Yu C; Wei H; Li Y; Zhang X; He F; Jiang Y
    J Proteome Res; 2011 Jun; 10(6):2797-806. PubMed ID: 21563774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency.
    Kirsch R; Clarkson V; Verdonk RC; Marais AD; Shephard EG; Ryffel B; de la M Hall P
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):174-82. PubMed ID: 16706830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.
    Targher G; Bertolini L; Rodella S; Zoppini G; Scala L; Zenari L; Falezza G
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):679-83. PubMed ID: 16712671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis.
    Chen C; Schmilovitz-Weiss H; Liu XE; Pappo O; Halpern M; Sulkes J; Braun M; Cohen M; Barak N; Tur-Kaspa R; Vanhooren V; Van Vlierberghe H; Libert C; Contreras R; Ben-Ari Z
    J Proteome Res; 2009 Feb; 8(2):463-70. PubMed ID: 19140676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease.
    Aigner E; Strasser M; Haufe H; Sonnweber T; Hohla F; Stadlmayr A; Solioz M; Tilg H; Patsch W; Weiss G; Stickel F; Datz C
    Am J Gastroenterol; 2010 Sep; 105(9):1978-85. PubMed ID: 20407430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
    Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE
    Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
    Koppe SW; Sahai A; Malladi P; Whitington PF; Green RM
    J Hepatol; 2004 Oct; 41(4):592-8. PubMed ID: 15464239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance.
    Yilmaz Y; Ulukaya E; Atug O; Dolar E
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1247-51. PubMed ID: 19474742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease.
    Vinaixa M; Rodríguez MA; Rull A; Beltrán R; Bladé C; Brezmes J; Cañellas N; Joven J; Correig X
    J Proteome Res; 2010 May; 9(5):2527-38. PubMed ID: 20402505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice.
    Karavia EA; Papachristou DJ; Kotsikogianni I; Giopanou I; Kypreos KE
    FEBS J; 2011 Sep; 278(17):3119-29. PubMed ID: 21740524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicometabolomics approach to urinary biomarkers for mercuric chloride (HgCl₂)-induced nephrotoxicity using proton nuclear magnetic resonance (¹H NMR) in rats.
    Kim KB; Um SY; Chung MW; Jung SC; Oh JS; Kim SH; Na HS; Lee BM; Choi KH
    Toxicol Appl Pharmacol; 2010 Dec; 249(2):114-26. PubMed ID: 20804780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents.
    Leikin-Frenkel A; Goldiner I; Leikin-Gobbi D; Rosenberg R; Bonen H; Litvak A; Bernheim J; Konikoff FM; Gilat T
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1205-13. PubMed ID: 18989145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
    Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
    J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet.
    de Lima VM; de Oliveira CP; Sawada LY; Barbeiro HV; de Mello ES; Soriano FG; Alves VA; Caldwell SH; Carrilho FJ
    Liver Int; 2007 Mar; 27(2):227-34. PubMed ID: 17311618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis.
    Rangnekar AS; Lammert F; Igolnikov A; Green RM
    Liver Int; 2006 Oct; 26(8):1000-5. PubMed ID: 16953841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.